Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk

Liam King(Scripps Research Institute), Erica Ollmann Saphire(La Jolla Institute for Immunology), Crystal L. Moyer(Scripps Research Institute), Kai Huang(Galveston College), Philipp A. Ilinykh(Houston Methodist), Pavlo Gilchuk(AstraZeneca (Japan)), James E. Crowe(Vanderbilt University Medical Center), Robin Bombardi(Vanderbilt University Medical Center), Brandyn R. West(Scripps Research Institute), Sean Hui(Scripps Research Institute), Andrew I. Flyak(Vanderbilt University), Alexander Bukreyev(Galveston College)
Nature Communications
April 17, 2019
10.1038/s41467-019-09732-7
Cited by 34

Related Papers

Potently neutralizing and protective human antibodies against SARS-CoV-2
|Nature|2020|1.2k
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
|Nature Medicine|2020|543
Taxonomy of the order Mononegavirales: update 2016
|Archives of Virology|2016|506